Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 8
2003 14
2004 13
2005 14
2006 16
2007 18
2008 14
2009 29
2010 29
2011 34
2012 51
2013 55
2014 60
2015 92
2016 94
2017 93
2018 97
2019 128
2020 112
Text availability
Article attribute
Article type
Publication date

Search Results

873 results
Results by year
Filters applied: . Clear all
Page 1
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. Tang J, et al. Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210. Nat Rev Drug Discov. 2018. PMID: 30482962 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Nat Rev Drug Discov. 2018 Nov;17(11):783-784. doi: 10.1038/nrd.2018.167. Epub 2018 Oct 19. Nat Rev Drug Discov. 2018. PMID: 30337722 No abstract available.
The global pipeline of cell therapies for cancer.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Among authors: tang j. Nat Rev Drug Discov. 2019 Oct;18(11):821-822. doi: 10.1038/d41573-019-00090-z. Nat Rev Drug Discov. 2019. PMID: 31673124 No abstract available.
Immunotherapy and targeted therapy combinations in metastatic breast cancer.
Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Esteva FJ, et al. Among authors: tang j. Lancet Oncol. 2019 Mar;20(3):e175-e186. doi: 10.1016/S1470-2045(19)30026-9. Lancet Oncol. 2019. PMID: 30842061 Review.
The global landscape of cancer cell therapy.
Tang J, Hubbard-Lucey VM, Pearce L, O'Donnell-Tormey J, Shalabi A. Tang J, et al. Nat Rev Drug Discov. 2018 Jul;17(7):465-466. doi: 10.1038/nrd.2018.74. Epub 2018 May 25. Nat Rev Drug Discov. 2018. PMID: 29795477 No abstract available.
Immuno-oncology drug development goes global.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Among authors: tang j. Nat Rev Drug Discov. 2019 Nov;18(12):899-900. doi: 10.1038/d41573-019-00167-9. Nat Rev Drug Discov. 2019. PMID: 31780841 No abstract available.
Trends in the global immuno-oncology landscape.
Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Tang J, et al. Nat Rev Drug Discov. 2018 Dec;17(12):922. doi: 10.1038/nrd.2018.202. Epub 2018 Oct 26. Nat Rev Drug Discov. 2018. PMID: 30361553
Targeting PKCĪ“ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, Chiu TJ, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Lee PC, et al. Among authors: tang j. Cancer Cell. 2018 Dec 10;34(6):954-969.e4. doi: 10.1016/j.ccell.2018.11.007. Cancer Cell. 2018. PMID: 30537515 Free PMC article.
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. Nie L, et al. Among authors: tang j. Nat Commun. 2019 Nov 8;10(1):5114. doi: 10.1038/s41467-019-13105-5. Nat Commun. 2019. PMID: 31704972 Free PMC article.
COPD: preclinical models and emerging therapeutic targets.
Barreiro E, Wang X, Tang J. Barreiro E, et al. Among authors: tang j. Expert Opin Ther Targets. 2019 Oct;23(10):829-838. doi: 10.1080/14728222.2019.1667976. Epub 2019 Sep 20. Expert Opin Ther Targets. 2019. PMID: 31512957 Review.
873 results
Jump to page
Feedback